相关实验视频
Updated: Jul 16, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
药房管理,以减少反复出现的低血糖症
Journal of the American Pharmacists Association : JAPhA
|September 11, 2023
概括
药剂师主导的住院低血糖症预警审查显著减少了5.1%的复发性低血糖事件. 该倡议通过确定病因和修改治疗来提高患者的安全性,证明药剂师干预在血糖控制中的价值.
科学领域:
- 住院患者的血糖管理.
- 临床药房服务 临床药房服务
- 患者安全倡议 患者安全倡议
背景情况:
- 住院低血糖症增加了发病率和死亡率,在初始事件发生后,后续发作的可能性更高.
- 联合委员会要求对所有低血糖事件进行根本原因分析.
- 药剂师参与血糖控制方案已被证明可以预防低血糖症.
研究的目的:
- 评估药剂师使用电子警报实时评估低血糖症对减少住院期间反复发生的低血糖事件的影响.
主要方法:
- 一个单一中心的回顾性观察研究比较了实施前后阶段 (2020年与2021年).
- 电子健康记录 (EHR) 警报因血糖<70 mg/dL和最近的低血糖药物被药剂师审查.
- 统计分析包括t测试和千平方测试来比较结果.
主要成果:
- 实施后观察到复发性低血糖事件的绝对减少5.1% (P < 0.001).
- 严重低血糖天数减少了0.6% (P = 0.269).
- 药剂师干预发生在4小时内,建议的接受率为92%.
结论:
- 药剂师主导的低血糖评价有效地减少住院患者的复发性低血糖事件.
- 这一倡议突出了药剂师在加强住院患者血糖控制和患者安全方面的关键作用.
相关概念视频
Hypoglycemia and Glucagon
294
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
294
Diabetes: Management and Pharmacotherapy
309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
203
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
203
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183
SBAR II: Application of SBAR
4.5K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230

